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Abstract
Background: There is limited data on the clinical outcome of patients with pandemic H1N1 (pH1N1) pneumonia who
received oseltamivir treatment, especially when the treatment was administered more than 48 hours after symptom onset.
Methods: During the pandemic in 2009, a cohort of pH1N1 influenza pneumonia was built in China, and their clinical
information was collected systematically, and analyzed with Cox models.
Results: 920 adults and 541 children with pneumonia who didn’t receive corticosteroids were analyzed. In-hospital mortality
was higher in adults who did not receive antiviral therapy (18.2%) than those with who received oseltamivir # 2days (2.9%),
between 2–5 days (4.6%) and .5 days after illness onset (4.9%), p,0.01. A similar trend was observed in pediatric patients.
Cox regression showed that at 60 days after symptoms onset, 11 patients (10.8%) who did not receive antivirals died versus
4 (1.8%), 18 (3.3%), and 23 (3.7%) patients whose oseltamivir treatment was started # 2days, between 2–5days, and .5
days, respectively. For males patients, aged $ 14 years and baseline PaO2/FiO2,200, oseltamivir administration reduced the
mortality risk by 92.1%, 88% and 83.5%, respectively. Higher doses of oseltamivir (.3.8 mg/kg/d) did not improve clinical
outcome (mortality, higher dose 2.5% vs standard dose 2.8%, p.0.05).
Conclusions: Antiviral therapy might reduce mortality of patients with pH1N1 pneumonia, even when initiated more than
48 hours after onset of illness. Greater protective effects might be in males, patients aged 14–60 years, and patients with
PaO2/FiO2,200.
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Introduction
In early April 2009, human infections caused by influenza A
pandemic H1N1 (pH1N1) 2009 virus were identified in the United
States [1] and Mexico [2] and spread rapidly to other regions of
the world, resulting in the first influenza pandemic since 1968 [3].
As of March 2010, almost all countries had reported laboratory-
confirmed cases, and more than 17,700 deaths had been reported
to the World Health Organization (WHO) [4]. pH1N1 virus
infection causes disease requiring hospitalisation of previously fit
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29652individuals as well as those with underlying conditions [5]. In the
United States, an estimated 59 million illnesses, 265,000
hospitalizations, and 12,000 deaths had been caused by the
2009 H1N1 virus as of mid-February 2010 [6]. In mainland
China, there were more than 127,000 laboratory confirmed cases
and 793 deaths as of February 28, 2010 [7].
Currently, no randomized controlled trial (RCT) of neuramin-
idase-inhibitor treatment of patients with influenza viral pneumo-
nia has been conducted. Observational studies have suggested that
oseltamivir therapy of adults hospitalized with seasonal influenza
(22%–43% of these patients had viral pneumonia) may reduce
mortality [8–10]. During this pandemic, although antiviral
therapy was recommended [11], evidence was still limited about
the correlation between oseltamivir treatment and clinical
outcome, including hospitalization [12], admission to intensive
care units (ICUs), and even death [13–15], especially for patients
with pH1N1 pneumonia who were started on antiviral therapy
.48 hours after illness onset [16].
During this pandemic, the National Influenza A pH1N1 2009
Clinical Investigation Group of China screened 3570 hospitalized
patients with pH1N1 virus infection, and at last built a cohort of
3066 patients with pneumonia caused by 2009 pH1N1 virus. This
large database gave us the opportunity to assess the effectiveness of
oseltamivir treatment for pneumonia caused by 2009 pH1N1
virus. We also analyzed the optimal timing and dosing of
oseltamivir in the treatment of 2009 pH1N1 pneumonia both in
adults and in children.
Methods
Data sources
Participating centers were identified by the National Influenza
A pH1N1 2009 Clinical Investigation Group of China. This is a
national network for the diagnosis and treatment of pH1N1, and
includes the Chinese Disease Control and Prevention (CDC) and
community hospitals and teaching hospitals around China that are
under the guidance by the Chinese Ministry of Health (MOH).
Hospitalized patients were included in this study if they met the
diagnostic criteria of having new radiographic abnormality
indicating pneumonia with laboratory-confirmed case of pH1N1
virus between September 1 and December 31, 2009. Pneumonia
was defined as an acute lower respiratory tract illness with two or
more of the following symptoms or signs: cough, productive
sputum, fever, chills, dyspnea, pleuritic chest pain, crackles, and
bronchial breathing plus an opacity or infiltrate seen on a chest
radiography that was interpreted as pneumonia by the treating
physicians. Both adult and child inpatients were included.
According to the pH1N1 2009 Clinical guideline (Third Edition,
2009) released by China MOH, a severe or critical case was
defined as those who met at leaset one of the following criteria on
admission: (1) respiratory failure; (2) septic shock; (3) multiple
organs insufficiency; (4) other critical clinical conditions requiring
intensive care. Hospitalized patients were excluded if they did not
have pneumonia. Patients were also excluded if they had been
treated as outpatients or in emergency rooms, had a duration of
hospitalization ,24 hours, or if there was an incomplete record of
clinical outcome [17]. All patients who were treated with
corticosteroids were also excluded in order to reduce any bias
from corticosteroids treatment as far as possible.
Antiviral therapeutic regimen
Based on local guidelines, antiviral therapy was considered for
severe cases and high risk patients who had been infected with
pH1N1 virus within 48 hours from onset of illness, no matter they
had pneumonia or not. For patients who presented pH1N1
influenza-like symptoms as fever (.=38uC), cough, and sore
throat for more than 2 days, the managing physicians were
allowed to make their own decisions regarding antiviral use.
Oseltamivir, for patients older than 12 years, was prescribed
according to the standard dosing regimen (75 mg twice daily
orally, for 5 days). Dosage adjustment, if necessary, was made
according to the patient’s renal function (75 mg daily, if
creatinine clearance ,30 ml/min). For children (1–12 years of
age), dosage adjustment was made according to body weight
(BW), that is: 30 mg Bid for children with BW,15 kg, 45 mg Bid
for BW 15–23 kg, 60 mg Bid for BW 23–40 kg, 75 mg Bid for
BW.40 kg.
Oseltamivir treatment was defined as at least 1 day of drug
therapy received by a patient. The time interval between symptom
onset and the administration of the first dose of oseltamivir was
calculated for each patient. The definition of standard dose was
oseltamivir # 3.8 mg/kg/d, and a higher dose oseltamivir
.3.8 mg/kg/d for more than 3 days (Figure S2).
Laboratory Confirmation
Pharyngeal or nasopharyngeal swabs were collected from all
patients. We used the protocol set by the US Centers for Disease
Control and Prevention, real-time RT-PCR for swine influenza A
(H1N1) as recommended by the WHO [18].
Data collection
Data collection and analysis were coordinated by the Chinese
MOH. A standard data collection form was used at each site. Site
investigators were primarily infectious disease physicians closely
involved in taking care of such patients at their centers. They were
asked to submit all cases that had been noted based on above
inclusion and exclusion criteria. Clinical information was collected
systematically from admission to discharge for each patient. A
trained team of physicians and medical students reviewed the
patient charts and recorded demographic, clinical, and laboratory
information, chest X-ray, results of diagnostic testing for influenza,
antiviral and corticosteroid treatment, non-invasive or invasive
ventilation, clinical complications and outcome. The data was
entered in duplicate into a computerized database. The data were
analyzed anonymously. The research ethics board at Beijing
Chao-Yang Hospital and First Affiliated Hospital, School of
Medicine, Zhejiang University approved the study, and the
consent statement was in written form.
Statistical Analysis
The main outcome was all-cause mortality that occurred during
a given hospital stay.
Means (standard deviations) or medians (interquartiles, IQR)
were calculated as summaries of continuous variables. For
categorical variables, percentages of patients in each category
were calculated. We compared clinical characteristics and clinical
outcomes by an ANOVA test, chi-square test, and Fisher’s exact
test, as appropriate. Cox model with time-varying treatment
variable; categorical variable for time from symptom-onset; and an
interaction between these two variables was performed to identify
the protective effects of oseltamivir and to avoid survivor bias. In
the model, survival time was treated as time variable, and death as
status, antiviral therapy, its initial time and its interaction with
initial time as covariates. A survival plot, separate lines for antiviral
therapy and its initial time, was used to identify the protective
effects of oseltamivir in the study. All analyses were carried out
using SPSS for Windows (release 13.0).
Antiviral for pH1N1 Pneumonia
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Clinical description of cohort
Altogether, 3570 hospitalized cases were screened among them
3066 patients had pneumonia. The patient cohort was identified
from 424 hospitals in 27 provinces in mainland China. This
cohort represented approximately 11.7% of all patients hospital-
ized for pH1N1, and 48.7% (n=347) of all deaths due to pH1N1
in mainland China during the study period (lab-confirmed cases
116762; hospitalized cases 29719; death cases 713). After
exclusion patients who received corticosteroids, a total of 1461
patients (920 adults and 541 children) were included in the final
analysis on the effects of antiviral therapy on mortality.
(Figure 1).
Among 1461 patients, the mean age was 23.3(IQR: 5.2–41.3)
years and 55.2% (807) were male. 8.0% (49) had a BMI .30 kg/
m2 The main coexisting diseases were cardiovascular diseases,
respiratory diseases, and diabetes mellitus, accounting for 13.4%
(207), 10.6% (164) and 5.9% (91), respectively. Pregnancy and
postpartum accounted for 7.8% (119) and 2.9% (44). Antibiotics,
oseltamivir, traditional Chinese medicine, antiviral plasma, or
convalescent plasma were prescribed to97.6% (1426), 93.6%
(1367), 51.5% (750), and 2.2% (32), respectively. 9.8% (143) were
mechanically ventilated. The median length of hospitalization was
Figure 1. Flow chart of patients enrolled and included in the analysis of the impact of antiviral therapy on mortality. *Missing data for
pneumonia (n=20); "missing data for corticosteroid (n=9); missing data for timing or whether oseltamivir was prescribed (n=109).
doi:10.1371/journal.pone.0029652.g001
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mortality among patients $60 yrs of age (Table S1).
Clinical outcomes and antiviral therapy among patients
with pneumonia
Description of basic conditions among the different
groups of antivirals. Detailed clinical data was available for
920 adults and 541 children (less than 14 years of age). The
median age of adults was 35.1 years (range 14–99 years). (Table
S2) Those given oseltamivir .5 days were older than patients
given oseltamivir 2–5 days after onset of illness (41.2 vs 36.7 years,
p,0.05). More pregnant women were given antiviral therapy than
non-pregnancy (p,0.05). There was no difference between the
four treatment groups (divided based on when/if they received
oseltamivir therapy) concerning BMI, smoking status, common
features of illness (hemoptysis, dyspnea, CNS symptoms and
leucopenia), complications from illness (ARDS, septic shock, acute
renal failure, liver damage, and bacterial co-infection), APACHE
II score, and SOFA score 24 hours after hospital admission.
Except for oseltamivir, the frequency of administration of other
treatments, including antibiotics, traditional Chinese Medicine,
oxygen therapy, and convalescent plasma was similar between
groups (p.0.05).
Comparison of clinical outcomes among the different
groups of antivirals. The in-hospital mortality was higher in
patients who did not receive antiviral therapy (18.2%, 8 died) than
those who received oseltamivir # 2days (2.9%, 4), between 2–5
days (4.6%, 15) and .5 days (4.9%, 18), p,0.01. After excluding
patients who died within 96 hours of illness onset, the in-hospital
mortality among the four groups was 16.3% (7), 2.9% (4), 4.6%
(15) and 4.9% (18), respectively (P,0.01).
However, taken comparison among the three treatment groups
into consideration, the in-hospital mortality had not significant
difference. But more patients who received oseltamivir .5 days
needed intubation and mechanical ventilation compared to those
who received oseltamivir # 2days (P,0.01) and 2–5 days after
illness onset (P,0.01). There was no difference in ICU admission
rates between the four groups.
The median age of children was 4.0 years (range, 27 days–14
years). (Table S3) Univariate analysis indicated that the trend of
in-hospital mortality between the four treatment groups was
similar to that found in adults, though no significance was found
(p=0.068). The mortality rates was 0% when oseltamivir
administration was # 2days, 1.0% when oseltamivir administra-
tion was 2–5days, 2.4% when oseltamivir administration .5 days
after illness onset, and 6.4% in the control.
Cox regression analysis on the mortality risk of the
different groups of antivirals. Cox regression analysis showed
that: after 5 days from the onset of symptoms, the survival
probability without antiviral therapy administration sharply
decreased with a cumulative mortality of 6.3% (7 patients), while
only 1, 1, and 0 patients died among patients who had antiviral
therapy initiated within 48 hours, between 2–5 days, and .5 days
after illness onset, respectively, All cumulative mortalities
accounted for less than 0.5% of cases (Figure 2). After 60 days
after the onset of symptoms, 11 (10.8%) patients lacking antiviral
therapy died, compared with 4 (1.8%) when oseltamivir was
administered # 2days, 18 (3.3%) 2–5days, and 23 (3.7%) .5 days
after illness onset. The median time from illness onset to death was
6 (IQR: 5–11) days among patients who did not receive antiviral
therapy, which was significantly shorter than among patients those
who received oseltamivir # 2days after symptom onset, with a
median time of 18 (IQR: 6.5–68.8) days.
Figure 2. Cox regression for survival probability of pneumonia patients with antiviral therapy (Oseltamivir).
doi:10.1371/journal.pone.0029652.g002
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the crude mortality risk was reduced by 83% among patients who
received oseltamivir (P,0.01). (Figure S1).
For males, oseltamivir reduced the mortality risk by 92.1%
(P,0.001). For patients aged $ 14 years, oseltamivir reduced the
mortality risk by 88% (P,0.0001). Among adult patients, the
protective effects of oseltamivir were greater in patients aged,60
years (P,0.05). For patients with baseline PaO2/FiO2,200,
antiviral therapy with oseltamivir reduced the mortality risk by
83.5% (P,0.01). The risk reduction was 66% for children
(age,14 years), 78% for female, and 90.8% for patients with
baseline PaO2/FiO2$200, but no significance was found
(Figure 3). Results of antiviral dosage and clinical outcomes
are shown in Table S4. There was no difference of in-hospital
mortality between patients treated with standard dose and higher
dose.
Discussion
This study has shown that the mortality due to pH1N1 viral
pneumonia was 3.9%, a little lower than that of previous report
[5]. The mortality due to pH1N1 viral pneumonia can be reduced
by antiviral therapy (oseltamivir), even if treatment is initiated
.48 hours after onset of illness. The findings have important
therapeutic implications.
Oseltamivir is a potent and specific neuraminidase inhibitor for
influenza viruses, and it inhibits replication of influenza A and B
viruses in vitro [19]. However, studies of uncomplicated seasonal
influenza cases have demonstrate that oseltamivir is effective only
if administered within 48 h of the onset of symptoms [20–22].
Two recent observational studies have shown that treatment with
oseltamivir may reduce mortality among hospitalized patients with
pH1N1 influenza A, but both studies were limited by small sample
sizes. One study in Mexico, which included 58 severe cases of
pH1N1 influenza A infection and excluded patients who died
within 72 hours of illness onset, found that survivors were more
likely to have received treatment with a neuraminidase inhibitor
than nonsurvivors (odds ratio 8.5, 95% CI 1.2–62.8) [16]. A
second study from New York City has shown that the 28
hospitalized patients with pH1N1 influenza A who died were less
likely to have received oseltamivir within two days of hospitaliza-
tion than the 98 patients who survived (61 versus 96 percent) [23].
In this study, after excluding patients who died within 96 hours of
illness onset, the in-hospital mortality was still higher in patients
who did not have antiviral therapy compared with those who
received oseltamivir treatment.
Figure 3. Estimates of hazard ratio for in-hospital mortality among patients with antiviral therapy, as compared with patients with
no antiviral therapy. For patients aged,14 yrs or .=14 yrs, adjusted for sex, and baseline APACHE II score; For age subgroup analysis among
patients aged.=14 yrs, adjusted for sex, and baseline APACHE II; for sex subgroup analysis among patients aged.=14 yrs, adjusted for age, and
baseline APACHE II; for baseline PaO2/FiO2, subgroup analysis among patients aged.=14 yrs, adjusted for age, and sex.
doi:10.1371/journal.pone.0029652.g003
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influenza viral pneumonia, clinicians should not delay antiviral
treatment while waiting for virological confirmation. In reality,
some patients infected with influenza may begin to deteriorate 4
to 5 days after symptom onset [24]. In this cohort, median time
from onset of illness to radiographic confirmation of pneumonia
was 4 days; 83.4% of adults and 86% of children were initiated
on antiviral therapy more than 48 hours from onset of illness.
Our novel finding shows that oseltamivir treatment prescribed
.2 days after onset still leads to survival benefit. As the viral load
clearance may be delayed, severe patients may benefit from
antiviral therapy even if initiated .48 hours after illness onset
[25,26]. Dr. Kelvin K. W et al demonstrated that in the ARDS-
death group caused by influenza A pH1N1, nasopharyngeal
influenza viral load decreased more slowly compared to mild
diseases, even after oseltamivir therapy [27]. In our recent report,
Influenza A pH1N1 virus RNA was still detectable in autopsy
lung tissue from a 44-year-old previously healthy man 25 days
after illness onset [28].
Greater protective effects of antiviral therapy among male
patients, those aged 14 to 60 years, and patients with PaO2/
FiO2,200 were our new findings. Several reasons should be
considered. First, the Pneumonia Severity Index (PSI) scored the
exact age for males and age minus 10 for females, meaning that
males were more likely to die from pneumonia than females.
Compared with females, males with severe pneumonia may
benefit more from antiviral therapy [29]. Second, the Mexico
study showed that 87% of death and 71% of cases of severe
pneumonia involved patients between 5 and 59 years of age. While
one third of the elderly subjects may have had cross-protective
antibodies against the pH1N1 virus [30], this data may reflect an
age shift to young and middle aged adults with severe disease as
seen in previous pandemics. [31] Young adults with severe
pneumonia may benefit more from antiviral therapy. Third,
patients who died had worse hypoxemia [16], which may account
for the greater protective effects of antiviral therapy among
patients with ARDS.
In our study, we did not find more survival benefit when
comparing administration of higher dose of oseltamivir compared
to standard dose for patients with influenza A pH1N1 pneumonia.
Our data suggested that for a patient weighing 40–78 kg,
treatment with oseltamivir 150 mg Bid (higher dose) was not
more effective than treatment with oseltamivir 75 mg Bid
(standard dose), in terms of in-hospital mortality. However, for a
patient who weighed more than 79 kg, oseltamvir 150 mg Bid was
acceptable because such a dose was regarded as his/her ‘‘standard
dose’’ (,3.8 mg/kg/d).
Our study has several limitations. Firstly, only a small number of
cases (45 adults and 49 children) did not receive any antiviral
therapy and acted as the ‘‘negative’’ control group. Secondly,
despite the use of a prospective standardized data collection form,
not all information was available for all patients.
In conclusion, this study of a large sample size has shown that
antiviral therapy may improve survival in patients with severe
pH1N1 viral pneumonia. Greater protective effects by antiviral
therapy against fatality were found in male patients, patients aged
14 to 60 years, and patients with PaO2/FiO2,200. Administra-
tion of a double dose of oseltamivir for patients whose body weight
was less than 78 kg conferred no additional survival benefit.
Supporting Information
Figure S1 The estimates of hazard ratio for in-hospital mortality
among patients with antiviral therapy, as compared with patients
with no antiviral therapy. Adjusted for age, sex, baseline APACHE
II score.
(TIF)
Figure S2 Classification criteria for of administration dose with
oseltamivir. The definition of standard dose and higher dose was
made based on frequency analysis of daily oseltamivir use. The
dosage of antiviral therapy with oseltamivir was transposed
according to each patient’ body weight. Then the distribution of
frequencies was described based on the patient’s daily dosage per
1 kg of body weight. There were significant two peaks, which
could be classified by 3.8 mg/kg/d (the mean daily dosage of
oseltamivir).
(TIF)
Table S1 Demographic details and outcomes among pneumo-
nia patients with complete oseltamivir treatment data (n=1461).
(DOC)
Table S2 Antiviral therapy and outcomes of influenza pH1N1
viral pneumonia in adults. { Adult: age.=14 ys. Data were
presented as no./total no. (%), if otherwise stated. { CNS system
symptoms: refers to one or more of the following symptoms:
insomnia, restlessness, hallucination, headache, dizziness and
abnormal behaviour. 1Acute renal failure: Serum Creatinine
increased by 2-fold or GFR decreased .50%, or urine,0.5 ml/
kg/h for at least 12 hours. " Acute liver damage: AST or ALT
.70 U/L, or Tbil .2 mg/dL. Drug associated neuropsycho-
logical symptoms: refers to any neuropsychological symptoms
which occurred during oseltamivir therapy in hospitals, such as
insomnia, restlessness, hallucination, headache, dizziness and
abnormal behaviour. $: Missing number was 1 among patients
who were not prescribed active antiviral therapy, 7 among patients
who were prescribed oseltamivir within 48 hours, 5 among
patients who were prescribed oseltamivir 2–5days from onset,
and 12 among patients who were prescribed oseltamivir 5 days
later from onset. *P ,0.05 and ** P,0.01. Comparison of
antiviral therapy groups (Patients who received oseltamivir #
2days, between 2–5 days and .5 days after illness onset) with
control group (Patients who were not prescribed active anti-
influenza therapy), by using Dunnett t (2-sided) test.
(DOC)
Table S3 Antiviral therapy and outcomes of influenza pH1N1
viral pneumonia in children £, China. £ Children: age,14 ys.
Data were presented as no./total no. (%), if otherwise stated. {
Immunosuppressant: patients with HIV/AIDS, or patients who
were prescribed immunosuppressant agents, or corticosteroids
(equivalent to prednisone 15 mg/d, 30 days). { CNS system
symptoms: refers to one or more of the following symptoms:
insomnia, restlessness, hallucination, headache, dizziness and
abnormal behaviour. 1Acute renal failure: Serum Creatinine
increased by 2-fold or GFR decreased .50%, or urine,0.5 ml/
kg/h for at least 12 hours. " Acute liver damage: AST or ALT
.70 U/L, or Tbil .2 mg/dL. Drug associated neuropsycho-
logical symptoms: refers to any neuropsychological symptoms
which occurred during oseltamivir therapy in hospitals, such as
insomnia, restlessness, hallucination, headache, dizziness and
abnormal behaviour. *P,0.05 and ** P,0.01. Comparison of
antiviral therapy groups (Patients who received oseltamivir #
2days, between 2–5 days and .5 days after illness onset) with
control group (Patients who were not prescribed active anti-
influenza therapy), by using Dunnett t (2-sided) test.
(DOC)
Table S4 Antiviral dosage and outcomes of influenza pH1N1
viral pneumonia. { Standard dose, oseltamivir # 3.8 mg/kg/d;
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symptoms: refers to one or more of the following symptoms:
insomnia, restlessness, hallucination, headache, dizziness and
abnormal behaviour. 1Acute renal failure: Serum Creatinine
increased by 2-fold or GFR decreased .50%, or urine,0.5 ml/
kg/h for at least 12 hours. " Acute liver damage: AST or ALT
.70 U/L, or Tbil .2 mg/dL. Drug associated neuropsycho-
logical symptoms: refers to any neuropsychological symptoms
which occurred during oseltamivir therapy in hospitals, such as
insomnia, restlessness, hallucination, headache, dizziness and
abnormal behaviour. *P,0.05 and ** P,0.01. Pairwise compar-
isons were performed using Dunnett t (2-sided) test. $: p=0.830 for
groups of lower dose and higher dose of oseltamivir. Missing
number was 7 among patients who were not prescribed any active
antiviral therapy, 15 among patients who were prescribed
oseltamivir with lower dose, 10 among patients who were
prescribed oseltamivir with higher dose.
(DOC)
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